337 related articles for article (PubMed ID: 21326215)
1. CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation.
Kofler DM; Chmielewski M; Rappl G; Hombach A; Riet T; Schmidt A; Hombach AA; Wendtner CM; Abken H
Mol Ther; 2011 Apr; 19(4):760-7. PubMed ID: 21326215
[TBL] [Abstract][Full Text] [Related]
2. CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack.
Chmielewski M; Hombach AA; Abken H
Gene Ther; 2011 Jan; 18(1):62-72. PubMed ID: 20944680
[TBL] [Abstract][Full Text] [Related]
3. Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice.
Gulati P; Rühl J; Kannan A; Pircher M; Schuberth P; Nytko KJ; Pruschy M; Sulser S; Haefner M; Jensen S; Soltermann A; Jungraithmayr W; Eisenring M; Winder T; Samaras P; Tabor A; Stenger R; Stupp R; Weder W; Renner C; Münz C; Petrausch U
Clin Cancer Res; 2018 Aug; 24(16):3981-3993. PubMed ID: 29748183
[No Abstract] [Full Text] [Related]
4. Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts.
Suryadevara CM; Desai R; Farber SH; Choi BD; Swartz AM; Shen SH; Gedeon PC; Snyder DJ; Herndon JE; Healy P; Reap EA; Archer GE; Fecci PE; Sampson JH; Sanchez-Perez L
Clin Cancer Res; 2019 Jan; 25(1):358-368. PubMed ID: 30425092
[TBL] [Abstract][Full Text] [Related]
5. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.
Guedan S; Chen X; Madar A; Carpenito C; McGettigan SE; Frigault MJ; Lee J; Posey AD; Scholler J; Scholler N; Bonneau R; June CH
Blood; 2014 Aug; 124(7):1070-80. PubMed ID: 24986688
[TBL] [Abstract][Full Text] [Related]
6. Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".
Hombach AA; Rappl G; Abken H
Mol Ther; 2013 Dec; 21(12):2268-77. PubMed ID: 23985696
[TBL] [Abstract][Full Text] [Related]
7. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation.
Haynes NM; Trapani JA; Teng MW; Jackson JT; Cerruti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
J Immunol; 2002 Nov; 169(10):5780-6. PubMed ID: 12421958
[TBL] [Abstract][Full Text] [Related]
8. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule.
Hombach A; Wieczarkowiecz A; Marquardt T; Heuser C; Usai L; Pohl C; Seliger B; Abken H
J Immunol; 2001 Dec; 167(11):6123-31. PubMed ID: 11714771
[TBL] [Abstract][Full Text] [Related]
9. CD28-ζ CAR T Cells Resist TGF-β Repression through IL-2 Signaling, Which Can Be Mimicked by an Engineered IL-7 Autocrine Loop.
Golumba-Nagy V; Kuehle J; Hombach AA; Abken H
Mol Ther; 2018 Sep; 26(9):2218-2230. PubMed ID: 30055872
[TBL] [Abstract][Full Text] [Related]
10. Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling.
Hombach AA; Abken H
Int J Cancer; 2011 Dec; 129(12):2935-44. PubMed ID: 22030616
[TBL] [Abstract][Full Text] [Related]
11. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.
Song DG; Ye Q; Poussin M; Harms GM; Figini M; Powell DJ
Blood; 2012 Jan; 119(3):696-706. PubMed ID: 22117050
[TBL] [Abstract][Full Text] [Related]
12. TCRs genetically linked to CD28 and CD3ε do not mispair with endogenous TCR chains and mediate enhanced T cell persistence and anti-melanoma activity.
Govers C; Sebestyén Z; Roszik J; van Brakel M; Berrevoets C; Szöőr Á; Panoutsopoulou K; Broertjes M; Van T; Vereb G; Szöllősi J; Debets R
J Immunol; 2014 Nov; 193(10):5315-26. PubMed ID: 25320284
[TBL] [Abstract][Full Text] [Related]
13. Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40.
Foster AE; Mahendravada A; Shinners NP; Chang WC; Crisostomo J; Lu A; Khalil M; Morschl E; Shaw JL; Saha S; Duong MT; Collinson-Pautz MR; Torres DL; Rodriguez T; Pentcheva-Hoang T; Bayle JH; Slawin KM; Spencer DM
Mol Ther; 2017 Sep; 25(9):2176-2188. PubMed ID: 28697888
[TBL] [Abstract][Full Text] [Related]
14. Potential therapeutic strategy for non-Hodgkin lymphoma by anti-CD20scFvFc/CD28/CD3zeta gene tranfected T cells.
Zheng Y; Yu K; Du J; Jiang L; Zhang S; Han Y; Yu P; Tan Y
J Exp Clin Cancer Res; 2010 Sep; 29(1):121. PubMed ID: 20815894
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/CD3zeta recombinant gene.
Yu K; Hu Y; Tan Y; Shen Z; Jiang S; Qian H; Liang B; Shan D
Leuk Lymphoma; 2008 Jul; 49(7):1368-73. PubMed ID: 18452062
[TBL] [Abstract][Full Text] [Related]
16. THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells.
Sun C; Shou P; Du H; Hirabayashi K; Chen Y; Herring LE; Ahn S; Xu Y; Suzuki K; Li G; Tsahouridis O; Su L; Savoldo B; Dotti G
Cancer Cell; 2020 Feb; 37(2):216-225.e6. PubMed ID: 32004441
[TBL] [Abstract][Full Text] [Related]
17. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.
Savoldo B; Ramos CA; Liu E; Mims MP; Keating MJ; Carrum G; Kamble RT; Bollard CM; Gee AP; Mei Z; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Dotti G
J Clin Invest; 2011 May; 121(5):1822-6. PubMed ID: 21540550
[TBL] [Abstract][Full Text] [Related]
18. Strong CD28 costimulation suppresses induction of regulatory T cells from naive precursors through Lck signaling.
Semple K; Nguyen A; Yu Y; Wang H; Anasetti C; Yu XZ
Blood; 2011 Mar; 117(11):3096-103. PubMed ID: 21245484
[TBL] [Abstract][Full Text] [Related]
19. Id1 expression promotes T regulatory cell differentiation by facilitating TCR costimulation.
Liu C; Wang HC; Yu S; Jin R; Tang H; Liu YF; Ge Q; Sun XH; Zhang Y
J Immunol; 2014 Jul; 193(2):663-672. PubMed ID: 24920844
[TBL] [Abstract][Full Text] [Related]
20. CD28-CAR-T cell activation through FYN kinase signaling rather than LCK enhances therapeutic performance.
Wu L; Brzostek J; Sakthi Vale PD; Wei Q; Koh CKT; Ong JXH; Wu LZ; Tan JC; Chua YL; Yap J; Song Y; Tan VJY; Tan TYY; Lai J; MacAry PA; Gascoigne NRJ
Cell Rep Med; 2023 Feb; 4(2):100917. PubMed ID: 36696897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]